316 related articles for article (PubMed ID: 27302169)
1. Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome.
You S; Knudsen BS; Erho N; Alshalalfa M; Takhar M; Al-Deen Ashab H; Davicioni E; Karnes RJ; Klein EA; Den RB; Ross AE; Schaeffer EM; Garraway IP; Kim J; Freeman MR
Cancer Res; 2016 Sep; 76(17):4948-58. PubMed ID: 27302169
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of PCS and PAM50 prostate cancer classification schemes.
Yoon J; Kim M; Posadas EM; Freedland SJ; Liu Y; Davicioni E; Den RB; Trock BJ; Karnes RJ; Klein EA; Freeman MR; You S
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):733-742. PubMed ID: 33531653
[TBL] [Abstract][Full Text] [Related]
3. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
4. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
[TBL] [Abstract][Full Text] [Related]
5. A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Jan YJ; Yoon J; Chen JF; Teng PC; Yao N; Cheng S; Lozano A; Chu GCY; Chung H; Lu YT; Chen PJ; Wang JJ; Lee YT; Kim M; Zhu Y; Knudsen BS; Feng FY; Garraway IP; Gao AC; Chung LWK; Freeman MR; You S; Tseng HR; Posadas EM
Theranostics; 2019; 9(10):2812-2826. PubMed ID: 31244925
[No Abstract] [Full Text] [Related]
6. Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.
Ketola K; Munuganti RSN; Davies A; Nip KM; Bishop JL; Zoubeidi A
Clin Cancer Res; 2017 Nov; 23(22):6923-6933. PubMed ID: 28899970
[No Abstract] [Full Text] [Related]
7. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Weiner AB; Liu Y; Hakansson A; Zhao X; Proudfoot JA; Ho J; Zhang JH; Li EV; Karnes RJ; Den RB; Kishan AU; Reiter RE; Hamid AA; Ross AE; Tran PT; Davicioni E; Spratt DE; Attard G; Lotan TL; Lee Kiang Chua M; Sweeney CJ; Schaeffer EM
Cancer; 2023 Jul; 129(14):2169-2178. PubMed ID: 37060201
[TBL] [Abstract][Full Text] [Related]
8. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.
Zhao SG; Chang SL; Erho N; Yu M; Lehrer J; Alshalalfa M; Speers C; Cooperberg MR; Kim W; Ryan CJ; Den RB; Freedland SJ; Posadas E; Sandler H; Klein EA; Black P; Seiler R; Tomlins SA; Chinnaiyan AM; Jenkins RB; Davicioni E; Ross AE; Schaeffer EM; Nguyen PL; Carroll PR; Karnes RJ; Spratt DE; Feng FY
JAMA Oncol; 2017 Dec; 3(12):1663-1672. PubMed ID: 28494073
[TBL] [Abstract][Full Text] [Related]
9. Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes.
Pascal LE; Vêncio RZ; Page LS; Liebeskind ES; Shadle CP; Troisch P; Marzolf B; True LD; Hood LE; Liu AY
BMC Cancer; 2009 Dec; 9():452. PubMed ID: 20021671
[TBL] [Abstract][Full Text] [Related]
10. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes.
Chappidi MR; Sjöström M; Greenland NY; Cowan JE; Baskin AS; Shee K; Simko JP; Chan E; Stohr BA; Washington SL; Nguyen HG; Quigley DA; Davicioni E; Feng FY; Carroll PR; Cooperberg MR
Eur Urol Oncol; 2024 Apr; 7(2):222-230. PubMed ID: 37474400
[TBL] [Abstract][Full Text] [Related]
12. Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression.
Luca BA; Moulton V; Ellis C; Connell SP; Brewer DS; Cooper CS
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32708551
[TBL] [Abstract][Full Text] [Related]
13. Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis.
Cho H; Chung JI; Kim J; Seo WI; Lee CH; Morgan TM; Byun SS; Chung JS; Han KH
Cancer Sci; 2021 Feb; 112(2):859-870. PubMed ID: 33232539
[TBL] [Abstract][Full Text] [Related]
14. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
Seiler R; Ashab HAD; Erho N; van Rhijn BWG; Winters B; Douglas J; Van Kessel KE; Fransen van de Putte EE; Sommerlad M; Wang NQ; Choeurng V; Gibb EA; Palmer-Aronsten B; Lam LL; Buerki C; Davicioni E; Sjödahl G; Kardos J; Hoadley KA; Lerner SP; McConkey DJ; Choi W; Kim WY; Kiss B; Thalmann GN; Todenhöfer T; Crabb SJ; North S; Zwarthoff EC; Boormans JL; Wright J; Dall'Era M; van der Heijden MS; Black PC
Eur Urol; 2017 Oct; 72(4):544-554. PubMed ID: 28390739
[TBL] [Abstract][Full Text] [Related]
15. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer.
Jiang R; Lu YT; Ho H; Li B; Chen JF; Lin M; Li F; Wu K; Wu H; Lichterman J; Wan H; Lu CL; OuYang W; Ni M; Wang L; Li G; Lee T; Zhang X; Yang J; Rettig M; Chung LW; Yang H; Li KC; Hou Y; Tseng HR; Hou S; Xu X; Wang J; Posadas EM
Oncotarget; 2015 Dec; 6(42):44781-93. PubMed ID: 26575023
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling identifies clinically relevant subtypes of prostate cancer.
Lapointe J; Li C; Higgins JP; van de Rijn M; Bair E; Montgomery K; Ferrari M; Egevad L; Rayford W; Bergerheim U; Ekman P; DeMarzo AM; Tibshirani R; Botstein D; Brown PO; Brooks JD; Pollack JR
Proc Natl Acad Sci U S A; 2004 Jan; 101(3):811-6. PubMed ID: 14711987
[TBL] [Abstract][Full Text] [Related]
18. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
19. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
[TBL] [Abstract][Full Text] [Related]
20. Integrative molecular profiling of routine clinical prostate cancer specimens.
Grasso CS; Cani AK; Hovelson DH; Quist MJ; Douville NJ; Yadati V; Amin AM; Nelson PS; Betz BL; Liu CJ; Knudsen KE; Cooney KA; Feng FY; McDaniel AS; Tomlins SA
Ann Oncol; 2015 Jun; 26(6):1110-1118. PubMed ID: 25735316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
